1. Home
  2. DMAC vs SSP Comparison

DMAC vs SSP Comparison

Compare DMAC & SSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DMAC
  • SSP
  • Stock Information
  • Founded
  • DMAC 2000
  • SSP 1878
  • Country
  • DMAC United States
  • SSP United States
  • Employees
  • DMAC N/A
  • SSP N/A
  • Industry
  • DMAC Biotechnology: Pharmaceutical Preparations
  • SSP Broadcasting
  • Sector
  • DMAC Health Care
  • SSP Industrials
  • Exchange
  • DMAC Nasdaq
  • SSP Nasdaq
  • Market Cap
  • DMAC 310.1M
  • SSP 264.1M
  • IPO Year
  • DMAC N/A
  • SSP 1988
  • Fundamental
  • Price
  • DMAC $6.87
  • SSP $2.84
  • Analyst Decision
  • DMAC Strong Buy
  • SSP Buy
  • Analyst Count
  • DMAC 3
  • SSP 2
  • Target Price
  • DMAC $12.33
  • SSP $5.50
  • AVG Volume (30 Days)
  • DMAC 448.5K
  • SSP 478.0K
  • Earning Date
  • DMAC 11-12-2025
  • SSP 11-03-2025
  • Dividend Yield
  • DMAC N/A
  • SSP N/A
  • EPS Growth
  • DMAC N/A
  • SSP N/A
  • EPS
  • DMAC N/A
  • SSP 0.48
  • Revenue
  • DMAC N/A
  • SSP $2,439,152,000.00
  • Revenue This Year
  • DMAC N/A
  • SSP N/A
  • Revenue Next Year
  • DMAC N/A
  • SSP $9.92
  • P/E Ratio
  • DMAC N/A
  • SSP $5.96
  • Revenue Growth
  • DMAC N/A
  • SSP 5.25
  • 52 Week Low
  • DMAC $3.19
  • SSP $1.36
  • 52 Week High
  • DMAC $7.49
  • SSP $4.17
  • Technical
  • Relative Strength Index (RSI)
  • DMAC 63.84
  • SSP 45.50
  • Support Level
  • DMAC $6.83
  • SSP $2.73
  • Resistance Level
  • DMAC $7.41
  • SSP $3.00
  • Average True Range (ATR)
  • DMAC 0.43
  • SSP 0.16
  • MACD
  • DMAC 0.03
  • SSP -0.02
  • Stochastic Oscillator
  • DMAC 73.62
  • SSP 26.83

About DMAC DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

About SSP E.W. Scripps Company (The)

The E W Scripps Co is a media enterprise with interests in local and national media brands. It owns and operates a collection of daily and community newspapers in medium-sized cities in the southern and western portions of the United States. The company's operating segment includes Local Media, Scripps Networks, and Other. It generates maximum revenue from the Local Media segment. The Local Media segment includes local broadcast stations and their related digital operations.

Share on Social Networks: